Two-year Update From CheckMate 141: Outcomes With Nivolumab...

International Journal of Radiation Oncology*Biology*Physics 2018 / 04 Vol. 100; Iss. 5

Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

Ferris, R.L., Blumenschein, G.R., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., Harrington, K., Kasper, S., Vokes, E.E., Even, C., Worden, F., Saba, N.F., Docampo, LCIglesias, Haddad, R.I., Ror
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
100
Language:
english
Journal:
International Journal of Radiation Oncology*Biology*Physics
DOI:
10.1016/j.ijrobp.2017.12.300
Date:
April, 2018
File:
PDF, 67 KB
english, 2018
Conversion to is in progress
Conversion to is failed